GGrantIndex
Sort

8,912 grants matching sars cov 2

Peripheral Tissue Biomarker for Premorten Diagnosis of Lewy Body Dementia

$975,214
Shu G Chen · Case Western Reserve University · R01 · FY2021 · NS

Investigating Individual Susceptibility and Host Response in Acute Respiratory Distress Syndrome

$975,000
Nuala Jennings Meyer · University Of Pennsylvania · R35 · FY2025 · HL

Investigating Individual Susceptibility and Host Response in Acute Respiratory Distress Syndrome

$975,000
Nuala Jennings Meyer · University Of Pennsylvania · R35 · FY2022 · HL

Investigating Individual Susceptibility and Host Response in Acute Respiratory Distress Syndrome

$975,000
Nuala Jennings Meyer · University Of Pennsylvania · R35 · FY2023 · HL

Genetics and pathophysiology of systemic juvenile idiopathic arthritis and other complex autoinflammatory diseases

$974,635
Michael Ombrello · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2023 · AR

THE COVID-19 PANDEMIC HAS DISPERSED A NEW STRAIN OF CORONAVIRUS (CALLED SARS-COV-2) THROUGHOUT THE WORLD. DURING THE RAPID GLOBAL SPREAD, THE NEW VIRUS CONTINUES TO MUTATE AND THERE ARE NOW NUMEROUS GENETIC VERSIONS OF SARS-COV-2. THE U.S. LIVESTOCK SECTOR PLAYS AN INDISPENSABLE ROLE IN THE SAFE AND RELIABLE FOOD SUPPLY, EMPLOYMENT, AND ECONOMIC DEVELOPMENT, SO IT IS CRITICAL TO UNDERSTAND IF SARS-COV-2 VIRUSES CAN POSE A THREAT TO LIVESTOCK. THE GOALS OF THIS PROJECT ARE TO INVESTIGATE THE SUSCEPTIBILITY OF LIVESTOCK TO SARS-COV-2 AND TO DETERMINE IF THE VIRUS MAY ADAPT AND EFFICIENTLY SPREAD AMONG LIVESTOCK. THE RESEARCH WILL USE A COMBINATION OF EXPERIMENTAL INFECTION STUDIES USING CELL CULTURES AND ANIMALS ALONG WITH COMPUTER MODELS TO ASSESS THE CHANCE FOR THE VIRUS TO EFFICIENTLY INFECT LIVESTOCK SPECIES. ADDITIONALLY, THE PROJECT WILL DEVELOP DIAGNOSTIC TESTS AND USE THEM TO MONITOR THE PRESENCE OF ANTIBODIES TO SARS-COV-2 IN LIVESTOCK ANIMALS. CHICKENS, CATTLE, AND PIGS ARE MAJOR ANIMAL AGRICULTURE SPECIES IN THE U.S., AND THROUGH THIS PROJECT, A BETTER UNDERSTANDING OF HOW SARS-COV-2 MAY AFFECT THEM WILL BE GAINED.

$974,311
The Pennsylvania State University · · FY2020 · National Institute of Food and Agriculture

THE WORLD IS FACING A CRISIS DUE TO THE COVID-19 PANDEMIC, WHICH HAS RESULTED IN THE CLOSURE OF MANY BUSINESSES. FOOD SUPPLY CHAIN PERSONNEL FROM FARM TO RETAIL LEVELS DO NOT HAVE THIS OPPORTUNITY TO WORK FROM HOME. MEANWHILE, KEEPING ALL WORKERS IN THE FOOD SUPPLY CHAINS HEALTHY AND SAFE IS CHALLENGING FOR STAKEHOLDERS. OUR KNOWLEDGE ABOUT SARS-COV-2 SURVIVAL ON FOODS, AND FOOD CONTACT SURFACES, AND IN RESPONSE TO DIFFERENT DISINFECTION METHODS, IS VERY LIMITED. IN ADDITION, THE FATE OF VIRUS AND HOW IT CAN BE TRANSFERRED THROUGH THE FOOD SUPPLY CHAIN HAS NOT BEEN ADDRESSED YET. THUS, THESE SIGNIFICANT LIMITATIONS HIGHLIGHTED THE UNMET NEEDS TO DEVELOP SYSTEMATIC RESEARCH APPROACHES, AND TRAINING MATERIALS FOR INDUSTRY. THE SPECIFIC AIMS OF THIS PROPOSED RESEARCH ARE: (A) ASSESS SURVIVAL OF SARS-COV-2 ON DIFFERENT FOODS, FOOD CONTACT SURFACES, AND PACKAGING MATERIALS UNDER DIFFERENT CONDITIONS; (B) DETERMINE THE EFFICACY OF DIFFERENT CONVENTIONALLY USED AND NOVEL SANITIZERS AGAINST SARS-COV-2 ON FOOD AND FOOD CONTACT SURFACES; (C) MEASURE THE TRANSFER RATE FROM HANDS TO FOODS AND FOOD CONTACT SURFACES TO BEST MIMIC THE FATE OF VIRUS; (D) DEVELOP EDUCATION MATERIALS FOR FOOD SUPPLY CHAIN STAKEHOLDERS, INCLUDING FARMERS, FOOD PRODUCTION WORKERS, FOOD RETAILERS AND CONSUMERS. BASED ON THIS SYSTEMATIC APPROACH, ADOPTABLE STRATEGIES WILL BE DEVELOPED ACROSS THE FOOD AND AGRICULTURE INDUSTRY TO RAPIDLY RESPOND TO THE COVID-19 PANDEMIC.

$972,188
Virginia Polytechnic Institute & State University · · FY2020 · National Institute of Food and Agriculture

IN VITRO TESTING IN HUMAN CELL LINES FOR ANTIMICROBIAL ACTIVITY AGAINST SARS-COV-2

$971,739
Sara Cherry · University Of Pennsylvania · N02 · FY2021 · AI

Core-002

$971,739
Kenneth D Stuart · Seattle Children'S Hospital · U19 · FY2025 · AI

Structural Characterization of Coronavirus Antibodies Raised by Infection and Vaccination

$971,500
Pamela J Bjorkman · Rockefeller University · P01 · FY2023 · AI

International Studies of the Acquired Immune Deficiency Syndrome (AIDS)

$970,881
Andrew Redd · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI

Cerebrospinal Fluid in PASC: A Window into the COVID Mind

$970,664
Serena S Spudich · Yale University · R01 · FY2022 · MH

COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,

$969,746
Ted Ross · University Of Georgia · N01 · FY2020 · AI

COVID supplement: A multi-site study seeking to study immune responses developed after infection with SARS-CoV-2

$969,655
Ted Ross · University Of Georgia · N01 · FY2020 · AI

RNA: New Antimicrobial Strategies

$969,159
Adrian Ferrã‰-D'amar㉠· National Heart, Lung, And Blood Institute · ZIA · FY2023 · HL

MPOPHC: Quantitative design of effective testing-based policies through infection trajectory modeling

$968,765
Stephen Kissler · University Of Colorado At Boulder · · FY2025 · MPS

Monoclonal Antibody to Combat Pseudomonas Aeruginosa

$968,643
Joanna B. Goldberg · Emory University · R01 · FY2024 · AI

The economic and social impact of COVID-19 mitigation policies: A cross-country analysis of macro events

$968,248
Dean R Lillard · Ohio State University · R01 · FY2024 · AG

Mobile Health to Monitor Risk for COVID-19 and Improve Mental Health during the Pandemic

$968,064
Michael J Zvolensky · University Of Houston · R01 · FY2022 · MH

CK21-003, Oregon Child Absenteeism due to Respiratory Disease Study - 3

$967,373
Jonathan L Temte · University Of Wisconsin-Madison · U01 · FY2021 · CK

Broadly neutralizing SARS-CoV-2 peptidic knobs

$967,225
Vaughn Vasil Smider · Applied Biomedical Science Institute · R01 · FY2023 · AI

Project 4: Computational panbetaCoV immunogen design

$966,626
Rory Henderson · Duke University · P01 · FY2023 · AI

A Web Service for Fragment-based Selectivity Analysis of Drug Leads

$966,453
John Laurence Kulp III · Conifer Point Pharmaceuticals, Llc · R44 · FY2023 · GM

Culturally-targeted communication to promote SARS-CoV-2 antibody testing in saliva: Enabling evaluation of inflammatory pathways in COVID-19 racial disparities

$964,759
Todd William Lucas · Michigan State University · U01 · FY2023 · CA

Unraveling Cytotoxic and Thrombotic Signals in COVID-19

$963,672
Yogen Kanthi · National Heart, Lung, And Blood Institute · ZIA · FY2022 · HL